Atrosab

Drug Profile

Atrosab

Alternative Names: Anti-TNF-receptor-1 monoclonal antibody - Baliopharm; atrosab-MS

Latest Information Update: 24 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celonic
  • Developer Baliopharm AG; Celonic
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Type 1 tumour necrosis factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Inflammation
  • Preclinical Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 18 May 2016 Baliopharm AG has been acquired by Alvotech
  • 11 Feb 2013 Phase-I clinical trials in Inflammation (in healthy volunteers) in Germany (IV)
  • 29 Nov 2012 Atrosab is available for licensing in World as of 29 Nov 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top